1. Home
  2. ARL vs LCTX Comparison

ARL vs LCTX Comparison

Compare ARL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARL
  • LCTX
  • Stock Information
  • Founded
  • ARL 1999
  • LCTX 1990
  • Country
  • ARL United States
  • LCTX United States
  • Employees
  • ARL N/A
  • LCTX N/A
  • Industry
  • ARL Building operators
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ARL Real Estate
  • LCTX Health Care
  • Exchange
  • ARL Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • ARL 262.8M
  • LCTX 274.0M
  • IPO Year
  • ARL N/A
  • LCTX N/A
  • Fundamental
  • Price
  • ARL $16.16
  • LCTX $1.54
  • Analyst Decision
  • ARL
  • LCTX Strong Buy
  • Analyst Count
  • ARL 0
  • LCTX 4
  • Target Price
  • ARL N/A
  • LCTX $4.25
  • AVG Volume (30 Days)
  • ARL 1.7K
  • LCTX 1.2M
  • Earning Date
  • ARL 11-06-2025
  • LCTX 11-13-2025
  • Dividend Yield
  • ARL N/A
  • LCTX N/A
  • EPS Growth
  • ARL N/A
  • LCTX N/A
  • EPS
  • ARL N/A
  • LCTX N/A
  • Revenue
  • ARL $48,139,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • ARL N/A
  • LCTX N/A
  • Revenue Next Year
  • ARL N/A
  • LCTX $176.00
  • P/E Ratio
  • ARL N/A
  • LCTX N/A
  • Revenue Growth
  • ARL N/A
  • LCTX 76.43
  • 52 Week Low
  • ARL $9.43
  • LCTX $0.37
  • 52 Week High
  • ARL $18.28
  • LCTX $1.42
  • Technical
  • Relative Strength Index (RSI)
  • ARL 58.72
  • LCTX 76.21
  • Support Level
  • ARL $15.96
  • LCTX $1.20
  • Resistance Level
  • ARL $17.00
  • LCTX $1.42
  • Average True Range (ATR)
  • ARL 0.26
  • LCTX 0.08
  • MACD
  • ARL -0.02
  • LCTX 0.02
  • Stochastic Oscillator
  • ARL 55.32
  • LCTX 86.32

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: